These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Cancer SIGVAR: A semiautomated interpretation tool for germline variants of hereditary cancer-related genes. Li H; Liu S; Wang S; Zeng Q; Chen Y; Fang T; Zhang Y; Zhou Y; Zhang Y; Wang K; Yan Z; Qiang C; Xu M; Chai X; Yuan Y; Huang M; Zhang H; Xiong Y Hum Mutat; 2021 Apr; 42(4):359-372. PubMed ID: 33565189 [TBL] [Abstract][Full Text] [Related]
31. Yield and Utility of Germline Testing Following Tumor Sequencing in Patients With Cancer. Lincoln SE; Nussbaum RL; Kurian AW; Nielsen SM; Das K; Michalski S; Yang S; Ngo N; Blanco A; Esplin ED JAMA Netw Open; 2020 Oct; 3(10):e2019452. PubMed ID: 33026450 [TBL] [Abstract][Full Text] [Related]
32. Genomic sequencing in cancer. Tuna M; Amos CI Cancer Lett; 2013 Nov; 340(2):161-70. PubMed ID: 23178448 [TBL] [Abstract][Full Text] [Related]
33. Evaluation of the pathogenic potential of germline DDX41 variants in hematopoietic neoplasms using the ACMG/AMP guidelines. Matsui H; Hirata M Int J Hematol; 2024 May; 119(5):552-563. PubMed ID: 38492200 [TBL] [Abstract][Full Text] [Related]
34. The Clinical Genome and Ancestry Report: An interactive web application for prioritizing clinically implicated variants from genome sequencing data with ancestry composition. Lee IH; Negron JA; Hernandez-Ferrer C; Alvarez WJ; Mandl KD; Kong SW Hum Mutat; 2020 Feb; 41(2):387-396. PubMed ID: 31691385 [TBL] [Abstract][Full Text] [Related]
35. Half of germline pathogenic and likely pathogenic variants found on panel tests do not fulfil NHS testing criteria. Andoni T; Wiggins J; Robinson R; Charlton R; Sandberg M; Eeles R Sci Rep; 2022 Feb; 12(1):2507. PubMed ID: 35190596 [TBL] [Abstract][Full Text] [Related]
36. Pediatric Cancer Variant Pathogenicity Information Exchange (PeCanPIE): a cloud-based platform for curating and classifying germline variants. Edmonson MN; Patel AN; Hedges DJ; Wang Z; Rampersaud E; Kesserwan CA; Zhou X; Liu Y; Newman S; Rusch MC; McLeod CL; Wilkinson MR; Rice SV; Soussi T; Taylor JP; Benatar M; Becksfort JB; Nichols KE; Robison LL; Downing JR; Zhang J Genome Res; 2019 Sep; 29(9):1555-1565. PubMed ID: 31439692 [TBL] [Abstract][Full Text] [Related]
37. Germline potential should not be overlooked for cancer variants identified in tumour-only somatic mutation testing. Al-Shinnag M; Cheong PL; Goodwin A; Trent R; Yu B Pathology; 2024 Jun; 56(4):468-472. PubMed ID: 38627125 [TBL] [Abstract][Full Text] [Related]
38. Combinatorial batching of DNA for ultralow-cost detection of pathogenic variants. Stoltze UK; Hagen CM; van Overeem Hansen T; Byrjalsen A; Gerdes AM; Yakimov V; Rasmussen S; Bækvad-Hansen M; Hougaard DM; Schmiegelow K; Hjalgrim H; Wadt K; Bybjerg-Grauholm J Genome Med; 2023 Mar; 15(1):17. PubMed ID: 36918911 [TBL] [Abstract][Full Text] [Related]
39. Feasibility and Clinical Utility of Reporting Hereditary Cancer Predisposition Pathogenic Variants Identified in Research Germline Sequencing: A Prospective Interventional Study. Hutchcraft ML; Zhang S; Lin N; Pickarski JC; Belcher EA; Wei S; Bocklage T; Miller RW; Villano JL; Cavnar MJ; Kim J; Arnold SM; Ueland FR; Kolesar JM JCO Precis Oncol; 2024 Jan; 8():e2300266. PubMed ID: 38295319 [TBL] [Abstract][Full Text] [Related]